Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
14
BLRX Quote, Financials, Valuation and Earnings
Last price:
$0.20
Seasonality move
:
-8.21%
Day range:
$0.20 - $0.21
52-week range:
$0.19 - $1.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
1.98x
Volume:
921.1K
Avg. volume:
1.6M
1-year change:
-87.32%
Market cap:
$16.8M
Revenue:
$4.8M
EPS (TTM):
-$0.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLRX
BioLine Rx
|
$5.3M | -$0.11 | 60.8% | -100% | $13.75 |
|
CANF
Can Fite Biofarma
|
$150K | -- | -23.47% | -1.43% | -- |
|
CGEN
Compugen
|
$17.7M | $0.21 | -25.41% | -- | -- |
|
PHGE
BiomX
|
-- | -$0.40 | -- | -35.19% | -- |
|
PLUR
Pluri
|
-- | -- | -- | -- | -- |
|
XTLB
XTL Biopharmaceuticals
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLRX
BioLine Rx
|
$0.20 | $13.75 | $16.8M | -- | $0.00 | 0% | 0.69x |
|
CANF
Can Fite Biofarma
|
$1.48 | -- | $9M | -- | $0.00 | 0% | 13.42x |
|
CGEN
Compugen
|
$1.54 | -- | $137.9M | 51.33x | $0.00 | 0% | 2.30x |
|
PHGE
BiomX
|
$0.62 | -- | $11.3M | -- | $0.00 | 0% | -- |
|
PLUR
Pluri
|
$4.82 | -- | $26.8M | -- | $0.00 | 0% | 42.82x |
|
XTLB
XTL Biopharmaceuticals
|
$1.44 | -- | $7.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLRX
BioLine Rx
|
76.58% | 3.064 | 64.84% | 1.33x |
|
CANF
Can Fite Biofarma
|
-- | 0.514 | -- | -- |
|
CGEN
Compugen
|
-- | 6.925 | -- | 4.14x |
|
PHGE
BiomX
|
-- | 0.964 | -- | -- |
|
PLUR
Pluri
|
126.31% | 2.721 | 65.82% | 5.60x |
|
XTLB
XTL Biopharmaceuticals
|
-- | 1.784 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLRX
BioLine Rx
|
$4.1M | -$5.4M | -66.36% | -160.88% | -84.91% | -$9.8M |
|
CANF
Can Fite Biofarma
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen
|
$13.5M | $4.5M | 2.69% | 2.69% | 26.24% | -- |
|
PHGE
BiomX
|
-- | -$10.5M | -- | -- | -- | -$8.1M |
|
PLUR
Pluri
|
$200K | -$5.2M | -74.75% | -438.78% | -1784.97% | -$4.3M |
|
XTLB
XTL Biopharmaceuticals
|
-- | -$175K | -- | -- | -- | -- |
BioLine Rx vs. Competitors
-
Which has Higher Returns BLRX or CANF?
Can Fite Biofarma has a net margin of -117.78% compared to BioLine Rx's net margin of --. BioLine Rx's return on equity of -160.88% beat Can Fite Biofarma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLine Rx83.37% -$0.07 $36.3M CANFCan Fite Biofarma-- -- -- -
What do Analysts Say About BLRX or CANF?
BioLine Rx has a consensus price target of $13.75, signalling upside risk potential of 2179.92%. On the other hand Can Fite Biofarma has an analysts' consensus of -- which suggests that it could grow by 845.95%. Given that BioLine Rx has higher upside potential than Can Fite Biofarma, analysts believe BioLine Rx is more attractive than Can Fite Biofarma.
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLine Rx0 0 0 CANFCan Fite Biofarma0 0 0 -
Is BLRX or CANF More Risky?
BioLine Rx has a beta of 1.394, which suggesting that the stock is 39.435% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.764%.
-
Which is a Better Dividend Stock BLRX or CANF?
BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or CANF?
BioLine Rx quarterly revenues are $4.9M, which are larger than Can Fite Biofarma quarterly revenues of --. BioLine Rx's net income of -$5.8M is higher than Can Fite Biofarma's net income of --. Notably, BioLine Rx's price-to-earnings ratio is -- while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.69x versus 13.42x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLine Rx0.69x -- $4.9M -$5.8M CANFCan Fite Biofarma13.42x -- -- --
-
Which has Higher Returns BLRX or CGEN?
Compugen has a net margin of -117.78% compared to BioLine Rx's net margin of 7.45%. BioLine Rx's return on equity of -160.88% beat Compugen's return on equity of 2.69%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLine Rx83.37% -$0.07 $36.3M CGENCompugen78.98% $0.01 $60.5M -
What do Analysts Say About BLRX or CGEN?
BioLine Rx has a consensus price target of $13.75, signalling upside risk potential of 2179.92%. On the other hand Compugen has an analysts' consensus of -- which suggests that it could grow by 159.74%. Given that BioLine Rx has higher upside potential than Compugen, analysts believe BioLine Rx is more attractive than Compugen.
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLine Rx0 0 0 CGENCompugen0 0 0 -
Is BLRX or CGEN More Risky?
BioLine Rx has a beta of 1.394, which suggesting that the stock is 39.435% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.818%.
-
Which is a Better Dividend Stock BLRX or CGEN?
BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or CGEN?
BioLine Rx quarterly revenues are $4.9M, which are smaller than Compugen quarterly revenues of $17.1M. BioLine Rx's net income of -$5.8M is lower than Compugen's net income of $1.3M. Notably, BioLine Rx's price-to-earnings ratio is -- while Compugen's PE ratio is 51.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.69x versus 2.30x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLine Rx0.69x -- $4.9M -$5.8M CGENCompugen2.30x 51.33x $17.1M $1.3M
-
Which has Higher Returns BLRX or PHGE?
BiomX has a net margin of -117.78% compared to BioLine Rx's net margin of --. BioLine Rx's return on equity of -160.88% beat BiomX's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLine Rx83.37% -$0.07 $36.3M PHGEBiomX-- $0.31 -- -
What do Analysts Say About BLRX or PHGE?
BioLine Rx has a consensus price target of $13.75, signalling upside risk potential of 2179.92%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1029.03%. Given that BioLine Rx has higher upside potential than BiomX, analysts believe BioLine Rx is more attractive than BiomX.
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLine Rx0 0 0 PHGEBiomX0 0 0 -
Is BLRX or PHGE More Risky?
BioLine Rx has a beta of 1.394, which suggesting that the stock is 39.435% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.
-
Which is a Better Dividend Stock BLRX or PHGE?
BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or PHGE?
BioLine Rx quarterly revenues are $4.9M, which are larger than BiomX quarterly revenues of --. BioLine Rx's net income of -$5.8M is lower than BiomX's net income of $9.6M. Notably, BioLine Rx's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.69x versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLine Rx0.69x -- $4.9M -$5.8M PHGEBiomX-- -- -- $9.6M
-
Which has Higher Returns BLRX or PLUR?
Pluri has a net margin of -117.78% compared to BioLine Rx's net margin of -1804.3%. BioLine Rx's return on equity of -160.88% beat Pluri's return on equity of -438.78%.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLine Rx83.37% -$0.07 $36.3M PLURPluri61.35% -$1.08 $25.3M -
What do Analysts Say About BLRX or PLUR?
BioLine Rx has a consensus price target of $13.75, signalling upside risk potential of 2179.92%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 563.9%. Given that BioLine Rx has higher upside potential than Pluri, analysts believe BioLine Rx is more attractive than Pluri.
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLine Rx0 0 0 PLURPluri0 0 0 -
Is BLRX or PLUR More Risky?
BioLine Rx has a beta of 1.394, which suggesting that the stock is 39.435% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.
-
Which is a Better Dividend Stock BLRX or PLUR?
BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or PLUR?
BioLine Rx quarterly revenues are $4.9M, which are larger than Pluri quarterly revenues of $326K. BioLine Rx's net income of -$5.8M is higher than Pluri's net income of -$5.9M. Notably, BioLine Rx's price-to-earnings ratio is -- while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.69x versus 42.82x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLine Rx0.69x -- $4.9M -$5.8M PLURPluri42.82x -- $326K -$5.9M
-
Which has Higher Returns BLRX or XTLB?
XTL Biopharmaceuticals has a net margin of -117.78% compared to BioLine Rx's net margin of --. BioLine Rx's return on equity of -160.88% beat XTL Biopharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BLRXBioLine Rx83.37% -$0.07 $36.3M XTLBXTL Biopharmaceuticals-- $0.10 -- -
What do Analysts Say About BLRX or XTLB?
BioLine Rx has a consensus price target of $13.75, signalling upside risk potential of 2179.92%. On the other hand XTL Biopharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 1983.33%. Given that BioLine Rx has higher upside potential than XTL Biopharmaceuticals, analysts believe BioLine Rx is more attractive than XTL Biopharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings BLRXBioLine Rx0 0 0 XTLBXTL Biopharmaceuticals0 0 0 -
Is BLRX or XTLB More Risky?
BioLine Rx has a beta of 1.394, which suggesting that the stock is 39.435% more volatile than S&P 500. In comparison XTL Biopharmaceuticals has a beta of 1.156, suggesting its more volatile than the S&P 500 by 15.571%.
-
Which is a Better Dividend Stock BLRX or XTLB?
BioLine Rx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLine Rx pays -- of its earnings as a dividend. XTL Biopharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLRX or XTLB?
BioLine Rx quarterly revenues are $4.9M, which are larger than XTL Biopharmaceuticals quarterly revenues of --. BioLine Rx's net income of -$5.8M is lower than XTL Biopharmaceuticals's net income of $485K. Notably, BioLine Rx's price-to-earnings ratio is -- while XTL Biopharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLine Rx is 0.69x versus -- for XTL Biopharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLRXBioLine Rx0.69x -- $4.9M -$5.8M XTLBXTL Biopharmaceuticals-- -- -- $485K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
